8-K: Serina Therapeutics Faces NYSE Delisting Threat

Serina Therapeutics received a notification from NYSE American regarding non-compliance with minimum stockholders' equity requirements, potentially leading to delisting.

Summary

• Serina Therapeutics received a notification from NYSE American on January 9, 2026, stating non-compliance with Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the Company Guide.
• The non-compliance stems from having stockholders' equity of $1.6 million as of September 30, 2025, and reporting losses in three of its four most recent fiscal years ended December 31, 2024.
• NYSE American requires minimum stockholders' equity of $2.0 million (with losses in two of three years), $4.0 million (with losses in three of four years), or $6.0 million (with losses in five of five years).
• The company must submit a plan by February 8, 2026, outlining actions to regain compliance by July 9, 2027, which marks an eighteen-month 'Cure Period' from the notification date.
• If the plan is not accepted by NYSE American, delisting proceedings will commence.
• The notice does not immediately impact the listing or trading of the company's common stock, nor does it affect ongoing business operations or SEC reporting requirements.

Sentiment

Score: 2

Explanation: The notification of non-compliance with NYSE listing standards and the explicit risk of delisting represent a significant negative event for the company, indicating severe financial distress and uncertainty regarding its future listing status and access to public markets.

Positives

• The NYSE American notice has no immediate impact on the listing or trading of the company's common stock.
• The notice does not affect the company's ongoing business operations or its reporting requirements with the Securities and Exchange Commission.
• The company has an opportunity to submit a plan to regain compliance and continue its listing during the Cure Period.
• Serina is a clinical-stage biotechnology company advancing its lead Investigational New Drug (IND) candidate, SER-252, for advanced Parkinson's disease, utilizing its proprietary POZ PlatformTM drug optimization technology.
• The company has a non-exclusive license agreement with Pfizer, Inc. to use its POZ polymer technology for lipid nanoparticle drug (LNP) delivery formulations.

Negatives

• The company is not in compliance with NYSE American minimum stockholders' equity requirements, reporting $1.6 million as of September 30, 2025, significantly below the required thresholds of $2.0 million, $4.0 million, or $6.0 million.
• The company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years ended December 31, 2024.
• There is a risk of delisting if the compliance plan is not accepted by NYSE American or if compliance is not regained within the specified Cure Period.
• The company is not currently eligible for any exemption from the stockholders' equity requirements under Section 1003(a) of the Company Guide.

Risks

• There is no assurance that the company will be able to achieve compliance with NYSE American listing standards within the Cure Period.
• If the plan to regain compliance is not accepted by NYSE American, delisting proceedings will commence.
• Uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates.
• The possibility of unfavorable new clinical data and further analyses of existing clinical data.
• The risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities.
• Whether regulatory authorities will be satisfied with the design of and results from clinical studies.
• Whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions, and whether and when regulatory authorities may approve any potential applications.
• Decisions by regulatory authorities impacting labeling, manufacturing processes, safety, and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates.
• Serina's ability to continue as a going concern.
• Competitive developments in the biotechnology industry.

Future Outlook

Serina Therapeutics intends to submit a plan to regain compliance with NYSE American listing standards by February 8, 2026, with a goal to achieve compliance by July 9, 2027. The company continues to advance its clinical programs, including SER-252 for Parkinson's disease, and explore additional applications of its POZ platform through partnerships. However, there can be no assurance that the company will be able to achieve compliance with such standards within the Cure Period, and actual results may differ materially from projections due to various risks inherent in research and development and regulatory processes.

Management Comments

• "The Company intends to submit the Plan to regain compliance with NYSE American listing standards, however there can be no assurance that the Company will be able to achieve compliance with such standards within the Cure Period."

Industry Context

Serina Therapeutics operates in the highly capital-intensive clinical-stage biotechnology sector, where companies often incur significant losses during the research and development phase before potential product commercialization. Non-compliance with exchange listing standards, particularly related to stockholders' equity and sustained losses, is a critical issue that can severely impact investor confidence and access to capital, which is vital for funding drug development. This situation highlights the financial fragility common among smaller biotech firms prior to market approval of their lead candidates, and the intense scrutiny they face regarding financial viability.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. The issue is a regulatory listing standard, not a performance comparison of operational or clinical results.

Stakeholder Impact

• Shareholders: Significant negative impact due to potential delisting, which could lead to a loss of liquidity, erosion of share value, and increased uncertainty regarding the company's future.
• Employees: Potential uncertainty regarding job security and company stability if financial distress worsens or delisting occurs, impacting company operations and morale.
• Customers/Partners: Potential impact on confidence in the company's long-term viability and ability to fulfill commitments, although immediate business operations are stated as unaffected.
• Creditors: Increased risk perception due to financial non-compliance and explicit mention of 'going concern' issues, potentially affecting terms for future financing.

Next Steps

• Submit a plan to NYSE American by February 8, 2026, detailing actions to regain compliance with listing standards.
• If the plan is accepted, continue listing during the Cure Period, subject to periodic reviews including quarterly monitoring for compliance with the plan.
• Regain compliance with NYSE American listing standards by July 9, 2027.
• Potentially appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide if the plan is not accepted.
• Continue advancing its lead Investigational New Drug (IND) candidate, SER-252, for advanced Parkinson's disease.
• Advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements.

Key Dates

Recommendation

The company faces a severe risk of delisting from the NYSE American due to insufficient stockholders' equity and a history of sustained losses. While a plan can be submitted, there is no assurance of its acceptance or successful compliance within the cure period. This situation signals significant financial distress and uncertainty regarding the company's ability to maintain its public listing, making the stock a high-risk investment with substantial downside potential, warranting a strong sell recommendation.

Keywords

Serina Therapeutics, NYSE American, Delisting, Stockholders' Equity, Non-compliance, Biotechnology, Clinical-stage, Parkinson's disease, SER-252, POZ Platform, SEC filing, 8-K